After the blowup of the biggest hope for Alzheimer’s, what’s next in the pipeline?
SEBASTIEN BOZON/AFP/GETTY IMAGES
The experimental drug known as aducanumab has long been seen as the next big hope on the horizon for Alzheimer’s patients — but that hope came crashing down on Thursday, when developer Biogen announced that it was halting two late-stage studies of the treatment after an interim analysis showed it was unlikely to work.
Other companies, though, are moving forward with experimental drugs of their own. Some target those familiar amyloid plaques and tau tangles, others look to inflammation and synapse regeneration, and still another mines young blood in search of therapeutic effect. Here’s a look at what’s next in the pipeline for a field that has generated no new approvals since 2003.
No hay comentarios:
Publicar un comentario